PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15219640-1 2004 Intravenous injections of CCK-B agonists, such as pentagastrin, produce symptoms of panic and potent activation of the human hypothalamic-pituitary-adrenal (HPA) axis. Pentagastrin 50-62 cholecystokinin B receptor Homo sapiens 26-31 18214880-3 2008 Subsequent transformation of 21 into an activated ester followed by the introduction of beta-alanine and tetragastrin led to the new pentagastrin drug 3 that contains a peptide moiety for targeting cancer cells expressing CCK-B/gastrin receptors. Pentagastrin 133-145 cholecystokinin B receptor Homo sapiens 222-227 17536796-1 2007 Starting from a novel, achiral 1,3,4-benzotriazepine-based CCK2 receptor antagonist, a process of optimization has afforded further compounds of this type that maintain the nanomolar affinity for recombinant, human CCK2 receptors and high selectivity over CCK1 receptors observed in the initial lead but display more potent inhibition of pentagastrin-stimulated gastric acid secretion in vivo. Pentagastrin 338-350 cholecystokinin B receptor Homo sapiens 59-72 18222546-1 2008 Pentagastrin is a cholecystokinin (CCK)-B agonist and laboratory panicogenic agent that produces endocrine (ACTH and cortisol), symptom (anxiety, panic) and cardiovascular (heart rate) responses. Pentagastrin 0-12 cholecystokinin B receptor Homo sapiens 18-41 10481831-8 1999 The HPA axis response to the CCK-B agonist pentagastrin may be a direct pharmacological effect. Pentagastrin 43-55 cholecystokinin B receptor Homo sapiens 29-34 15001623-3 2004 CCK and the CCK2-R agonist pentagastrin enhanced basal aldosterone secretion from ZG cells without affecting cortisol production from zona fasciculata-reticularis cells. Pentagastrin 27-39 cholecystokinin B receptor Homo sapiens 12-18 12529809-1 2003 RATIONALE: CCK(B) receptor agonists such as pentagastrin or CCK(4) have anxiogenic panic-like effects in humans. Pentagastrin 44-56 cholecystokinin B receptor Homo sapiens 11-26 12073167-0 2002 Anxiogenic effects of the CCK(B) agonist pentagastrin in humans and dose-dependent increase in plasma C-peptide levels. Pentagastrin 41-53 cholecystokinin B receptor Homo sapiens 26-32 12073167-1 2002 RATIONALE: Cholecystokinin type B (CCK(B)) receptor agonists such as pentagastrin or CCK-4 have panic-like anxiogenic effects in humans. Pentagastrin 69-81 cholecystokinin B receptor Homo sapiens 11-33 12073167-1 2002 RATIONALE: Cholecystokinin type B (CCK(B)) receptor agonists such as pentagastrin or CCK-4 have panic-like anxiogenic effects in humans. Pentagastrin 69-81 cholecystokinin B receptor Homo sapiens 35-51 11713976-2 2001 Exogenous administration of CCK-2 receptor agonists, such as cholecystokinin-tetrapeptide and pentagastrin, provoke panic attacks in man. Pentagastrin 94-106 cholecystokinin B receptor Homo sapiens 28-42 15157745-1 2004 The cholecystokinin (CCK-B) agonist pentagastrin stimulates dose-dependent release of adrenocorticotropin (ACTH) and cortisol in humans, likely via direct pharmacological action at pituitary CCK-B receptors. Pentagastrin 36-48 cholecystokinin B receptor Homo sapiens 21-26 15157745-1 2004 The cholecystokinin (CCK-B) agonist pentagastrin stimulates dose-dependent release of adrenocorticotropin (ACTH) and cortisol in humans, likely via direct pharmacological action at pituitary CCK-B receptors. Pentagastrin 36-48 cholecystokinin B receptor Homo sapiens 191-196 15001623-4 2004 The aldosterone response to CCK and pentagastrin was suppressed by a CCK2-R antagonist, but not by a CCK1-R antagonist. Pentagastrin 36-48 cholecystokinin B receptor Homo sapiens 69-75 15001623-6 2004 The cAMP response to pentagastrin was abrogated by CCK2-R antagonist or the adenylate cyclase inhibitor SQ-22536, and the aldosterone response was abolished by both SQ-22536 and the protein kinase A inhibitor H-89. Pentagastrin 21-33 cholecystokinin B receptor Homo sapiens 51-57 15001623-7 2004 Both CCK and pentagastrin increased steroidogenic acute regulatory protein mRNA expression in ZG cells; the effect was abrogated by CCK2-R antagonist. Pentagastrin 13-25 cholecystokinin B receptor Homo sapiens 132-138 12865901-4 2003 We used a double-blind placebo-controlled crossover design with randomization of the order of an injection of placebo and pentagastrin, a cholecystokinin-B receptor agonist that induces PAs in healthy volunteers (HVs). Pentagastrin 122-134 cholecystokinin B receptor Homo sapiens 138-164 12510010-1 2003 Intravenous injection of the cholecystokinin (CCK)-B receptor agonist, pentagastrin, produces robust, dose-dependent release of adrenocorticotropin (ACTH) and cortisol, supporting the hypothesis that CCK-B agonists pharmacologically activate the hypothalamic-pituitary-adrenal (HPA) axis. Pentagastrin 71-83 cholecystokinin B receptor Homo sapiens 200-205 11120398-0 2001 Dose response of arginine vasopressin to the CCK-B agonist pentagastrin. Pentagastrin 59-71 cholecystokinin B receptor Homo sapiens 45-50 11078001-1 2000 The CCK(B) agonist, pentagastrin, has been shown to induce anxiety in human subjects. Pentagastrin 20-32 cholecystokinin B receptor Homo sapiens 4-10 11078001-9 2000 The infusion of the CCK(B) agonist, pentagastrin (0.77, 1.92, and 3.84 microg/kg), decreased MPF in a time-related manner. Pentagastrin 36-48 cholecystokinin B receptor Homo sapiens 20-26 11078001-10 2000 The effects of pentagastrin 1.92 microg/kg were blocked by the CCK(B) antagonist, LY288513 (6.54 microg/kg). Pentagastrin 15-27 cholecystokinin B receptor Homo sapiens 63-69 10481831-0 1999 Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin. Pentagastrin 71-83 cholecystokinin B receptor Homo sapiens 57-62 7619662-4 1995 In Study 1 rapid intravenous injections of the CCK receptor subtype B (CCKB) agonist pentagastrin (0.15, 0.3 and 0.6 micrograms kg-1) were found to produce dose-related increases in subjective ratings of anxiety compared with placebo. Pentagastrin 85-97 cholecystokinin B receptor Homo sapiens 47-69 9689451-6 1998 Microinjections of the CCK-B agonist, pentagastrin, (0.5 and 1.0 nmol/0.25 microliter) facilitated the occurrence of defensive rage behavior. Pentagastrin 38-50 cholecystokinin B receptor Homo sapiens 23-28 23338219-16 1997 The anxiogenic/panicogenic action of CCK(B) agonists (CCK-4, pentagastrin) is even more pronounced in human studies, but the effectiveness of CCK(B) antagonists as anxiolytics remains unclear. Pentagastrin 61-73 cholecystokinin B receptor Homo sapiens 37-43 9137133-1 1997 OBJECTIVE: The anxiogenic and panicogenic effects of peripheral administration of the cholecystokinin-B receptor agonist pentagastrin and placebo were evaluated in patients with generalized anxiety disorder and normal comparison subjects. Pentagastrin 121-133 cholecystokinin B receptor Homo sapiens 86-112 26964658-4 1996 Similarly, in man, CCKB receptor agonists, like pentagastrin and CCK4, were found to be able to elicited panic attacks in both panic disorder (PD) patients and healthy volunteers. Pentagastrin 48-60 cholecystokinin B receptor Homo sapiens 19-23 8891258-0 1996 Intracerebroventricular infusion of the CCKB receptor agonist pentagastrin potentiates acoustic startle. Pentagastrin 62-74 cholecystokinin B receptor Homo sapiens 40-53 8782652-4 1996 CCK-B/gastrin receptors are therefore likely to be the molecular substrate for the pentagastrin-stimulation test, widely used in medullary thyroid carcinomas; moreover, they represent the targets for physiologically secreted gastrin or CCK which, as growth factors, may stimulate the growth of medullary thyroid carcinomas. Pentagastrin 83-95 cholecystokinin B receptor Homo sapiens 0-5 7619662-4 1995 In Study 1 rapid intravenous injections of the CCK receptor subtype B (CCKB) agonist pentagastrin (0.15, 0.3 and 0.6 micrograms kg-1) were found to produce dose-related increases in subjective ratings of anxiety compared with placebo. Pentagastrin 85-97 cholecystokinin B receptor Homo sapiens 71-75 9160584-2 1994 Recently, pentagastrin, a commercially available CCKB agonist, has been reported to have similar anxiogenic properties. Pentagastrin 10-22 cholecystokinin B receptor Homo sapiens 49-53 20931328-6 2011 CONCLUSION: These results show that the cholecystokinin-2 receptor agonist, pentagastrin, has the same effect as the mu-opioid receptor antagonist, naloxone, on placebo analgesia induced by morphine pre-conditioning, which suggests that the balance between cholecystokinergic and opioidergic systems is crucial in placebo responsiveness in pain. Pentagastrin 76-88 cholecystokinin B receptor Homo sapiens 40-66